Merck to Buy OncoImmune Amid Covid-19 Vaccine Development
The drugmaker is buying biopharmaceutical company OncoImmune, which has reported positive results from a late-stage study of a coronavirus vaccine candidate, for $425 million in cash.
- AstraZeneca says its coronavirus vaccine can be around 90 percent effective
- Dave Sidhu: Justice Alito was right — cancel culture in the law is dangerous
